SCHEMBL17512430

SCHEMBL17512430

COc1ccc(C(=O)Nc2cc(OC)c(OC)c(OC)c2)cc1NC(=O)C(C)C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.57
ATM Q13315 1/20 0.56
MAPT P10636 2/20 0.55
LMNA P02545 2/20 0.53
MAPK1 P28482 3/20 0.52
GAA P10253 1/20 0.52
P4HTM Q9NXG6 1/20 0.52
STAT3 P40763 1/20 0.52
HDAC1 Q13547 3/20 0.50
HDAC8 Q9BY41 3/20 0.50
HDAC6 Q9UBN7 3/20 0.50
NAMPT P43490 1/20 0.50
KDM4E B2RXH2 1/20 0.50
PDK1 Q15118 1/20 0.49
PDK2 Q15119 1/20 0.49
PDK3 Q15120 1/20 0.49
PDK4 Q16654 1/20 0.49
POLB P06746 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
TP53 P04637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17512412 0.90 ATM (0.54) SMN1; SMN2ATMMAPTLMNAMAPK1
SCHEMBL17507535 0.90 ATM (0.54) SMN1; SMN2ATMMAPTLMNAMAPK1
SCHEMBL17512395 0.89 MAPT (0.61) SMN1; SMN2ATMMAPTMAPK1POLB
SCHEMBL17512384 0.86 ATM (0.60) SMN1; SMN2ATMMAPTMAPK1GAA
SCHEMBL17512400 0.85 HDAC8 (0.63) SMN1; SMN2MAPTLMNAMAPK1GAA
SCHEMBL17512392 0.84 MAPT (0.54) SMN1; SMN2ATMMAPTLMNASTAT3
SCHEMBL17512387 0.84 MEN1 (0.68) SMN1; SMN2MAPTLMNAHDAC1HDAC8
SCHEMBL2217242 0.82 MAPT (0.56) SMN1; SMN2ATMMAPTLMNAMAPK1
SCHEMBL17512432 0.82 MEN1 (0.55) SMN1; SMN2ATMMAPTLMNAGAA
SCHEMBL17512407 0.82 MAPT (0.57) SMN1; SMN2MAPTMAPK1HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9688637-B2 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members NORTHWESTERN UNIVERSTIY (US) 2017-06-27 US disclosed
US-9688637-B2 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members NORTHWESTERN UNIVERSTIY (US) 2017-06-27 US disclosed
US-9688637-B2 3-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family members NORTHWESTERN UNIVERSTIY (US) 2017-06-27 US disclosed
US-20160052870-A1 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G AND OTHER A3 FAMILY MEMBERS NORTHWESTERN UNIVERSITY (US) 2016-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052870-A1 3-AMIDOBENZAMIDES AND USES THEREOF FOR INCREASING CELLULAR LEVELS OF A3G AND OTHER A3 FAMILY MEMBERS L3MBTL3, AFG3L2, AMPD3 SMN1; SMN2 3691/4885ATM 4232/4885MAPT 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.